PATENT CLAIM ANALYSIS

Application Number: 16264434
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-06
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

Claim (Index 13):
The method of  claim 1 , wherein the RAR  agonist is a RAR  agonist of general formula IV wherein R1 and R2 are independently H or C1-6 alkyl; R3 is H or F; and X is O, S, CH2, C(R4)2, or NR5, wherein R4 and R5 are independently H or C1-6 alkyl.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 99.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16034123', '16117372', '16034064', '15868469', '15620411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7846507635087028
- 35 USC 102 Novelty (BERT): 0.7551576945656545
- Combined Prediction Score: 0.7817014566143979
- Mean Citation Score: 608.9010599999998
- Max Citation Score: 917.8652
- Similarity Product: 846.488791512084

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test